Details of Drug-Drug Interaction
| Drug General Information (ID: DDI40IYFHD) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Ranitidine | Drug Info | Bosutinib | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiulcer Agents | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Ranitidine-Bosutinib Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered gastric pH Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Ranitidine | Bosutinib | |||||||
| Mechanism | Gastric alkalinizer | Gastric pH sensitive | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Gastric pH | ||||||||
| Factor Description | The normal pH range of gastric acid is between 1.5 and 3.5 and is highly acidic, consisting mainly of hydrochloric acid. Changes in the pH of the stomach can alter the absorption of drugs. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | To minimize the potential for interaction, H2-receptor antagonists or antacids should be administered at least 2 hours before or 2 hours after the bosutinib dose. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||||||||||||||||